Published in Women's Health Weekly, March 4th, 2004
In the largest prospective, randomized, controlled trial to date, 618 women were selected to receive estrogen replacement therapy (ERT) following surgery for stage I or II endometrial cancer and 618 women were selected randomly to receive a placebo. Both groups were treated for 3 years, with an additional 2 years of follow-up. Due to an enrollment drop in the study following the June 2002 publication of the Women's Health Initiative...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.